Rhizen Pharmaceuticals AG is a leading discovery and development company that specializes in differentiated products through cutting-edge science and strategic partnerships. With a focus on oncology and inflammation, the company has made significant progress in developing a diverse pipeline of assets. Some of their notable achievements include a partnership with TG Therapeutics for the development of TGR1202, which has advanced to Phase 1 clinical trials.

They have also entered into a licensing deal with Novartis AG for RP6557, targeting non-oncology indications. Rhizen Pharmaceuticals AG's leadership team consists of proven and seasoned professionals with expertise spanning the entire discovery-development-commercialization cycle. They bring together a wealth of knowledge and experience to drive the company's success.

With an end-to-end approach, Rhizen Pharmaceuticals AG offers capabilities to discover and develop novel oncology-focused new molecular entities (NMEs). They have a deep pipeline of assets and a strong track record of successful collaborations with global partners. Based in Basel, Switzerland, Rhizen Pharmaceuticals AG is a niche-focused biotech company with global operations and a shared vision across affiliates.

They have a strong presence in the field of oncology and strive to make advancements in the treatment of various indications